Research Papers

This database includes peer-reviewed publications authored or funded by TB Alliance. Use the tags on the right to filter by subject, or search for a particular author or term using the search bar.

Displaying 138 papers

Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis

9/2011 - Tasneen R, Li SY, Peloquin CA, et. al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother. 2011 Dec;55(12):5485-92. doi: 10.1128/AAC.05293-11

Tags: Bedaquiline (TMC-207), BPaZ, Clofazamine, Preclinical Data, Pretomanid/PA-824

Synthesis and Structure-activity Relationships of Varied Ether Linker Analogues of the Anti-tubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (

9/2011 - Thompson AM, Sutherland HS, Palmer BD, et. al. Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824).

Tags: Drug Discovery, Pharmacokinetics, Preclinical Data

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.

9/2011 - Diacon AH, Dawson R, von Groote-Bidlingmaier F, et. al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet. 2012 Sep 15;380(9846):986-93. doi: 10.1016/S0140-6736(12)61080-0.

Tags: Bedaquiline (TMC-207), Clinical Development, Clinical Trial Results, MDR-TB, Moxifloxacin, NC-001, PaMZ, Pretomanid/PA-824, Pyrazinamide

Challenges and opportunities in developing novel drugs for TB

9/2011 - Kaneko T, Cooper C, Mdluli K. Challenges and opportunities in developing novel drugs for TB. Future Med Chem. 2011 Sep;3(11):1373-400. doi: 10.4155/fmc.11.115.

Author(s): Takushi Kaneko, Christopher Cooper, Khisimuzi Mdluli

Tags: Advocacy, Drug Discovery, Editorials, Global Pipeline, Preclinical Models

Drugs for neglected diseases: part II

9/2011 - Kaneko T. Drugs for neglected diseases: part II. Future Med Chem. 2011 Sep;3(11):1329-30. doi: 10.4155/fmc.11.104.

Tags: Advocacy, Clinical Development, Drug Discovery, Editorials, Global Pipeline, TB Burden

Drug repositioning in the treatment of malaria and TB

9/2011 - Nzila A, Ma Z, Chibale K. Drug repositioning in the treatment of malaria and TB. Future Med Chem. 2011 Sep;3(11):1413-26. doi: 10.4155/fmc.11.95.

Author(s): Alexis Nzil, Zhenkun Ma, Kelly Chibale

Tags: Advocacy, Editorials, MDR-TB, TB Burden, XDR-TB

The TB Alliance: overcoming challenges to chart the future course of TB drug development

8/2011 - Ginsberg AM. The TB Alliance: overcoming challenges to chart the future course of TB drug development. Future Med Chem. 2011 Aug;3(10):1247-52. doi: 10.4155/fmc.11.82.

Tags: Advocacy, Editorials, Global Pipeline

Drugs for neglected diseases: part I

8/2011 - Kaneko T. Drugs for neglected diseases: part I. Future Med Chem. 2011 Aug;3(10):1235-7. doi: 10.4155/fmc.11.103.

Tags: Advocacy, Clinical Development, Drug Discovery, Editorials, Global Pipeline, TB Burden, TB-HIV

Implications of the current tuberculosis treatment landscape for future regimen change

6/2011 - Wells WA, Konduri N, Chen C, et.al. Implications of the current tuberculosis treatment landscape for future regimen change. Int J Tuberc Lung Dis. 2011 Jun;15(6):746-53. doi: 10.5588/ijtld.10.0094.

Tags: Drug-Sensitivity Testing, HRZE, MDR-TB, Policy, Regimen Change, TB Market

Size and Usage Patterns of Private TB Drug Markets in the High Burden Countries

5/2011 - Wells WA, Ge CF, Patel N, Oh T, Gardiner E, Kimerling ME. Size and usage patterns of private TB drug markets in the high burden countries. PLoS One. 2011 May 4;6(5):e18964. doi: 10.1371/journal.pone.0018964.

Tags: Policy, TB Burden, TB Drug Market, TB Market

Activity of the Fluoroquinolone DC-159a in the Initial and Continuation Phases of Treatment of Murine Tuberculosis

4/2011 - Vandal OH, Roberts JA, Odaira T, Schnappinger D, Nathan CF, Ehrt S. Acid-susceptible mutants of Mycobacterium tuberculosis share hypersusceptibility to cell wall and oxidative stress and to the host environment. J Bacteriol. 2009 Jan;191(2):625-31. doi: 1

Tags: Drug Discovery, Pharmacokinetics, Preclinical Data, XDR-TB

Towards new business models for R&D for novel antibiotics

3/2011 - So AD, Gupta N, Brahmachari SK, Towards new business models for R&D for novel antibiotics. Drug Resist Updat. 2011 Apr;14(2):88-94. doi: 10.1016/j.drup.2011.01.006.

Tags: Advocacy, Editorials

Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making

3/2011 - Wells WA, Brooks A. Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making. Health Res Policy Syst. 2011 Mar 31;9:15. doi: 10.1186/1478-4505-9-15.

Tags: Advocacy, Policy, Regimen Change, TB Market

Drugs in development for tuberculosis

12/2010 - Ginsberg AM, Drugs in development for tuberculosis. Drugs. 2010 Dec 3;70(17):2201-14. doi: 10.2165/11538170-000000000-00000.

Tags: Advocacy, Bedaquiline (TMC-207), Clinical Development, Editorials, Global Pipeline, Pretomanid/PA-824, Rifapentine, TB Burden

Tuberculosis regimen change in high-burden countries

12/2010 - Wells WA, Konduri N, Chen C, et.al. Tuberculosis regimen change in high-burden countries. Int J Tuberc Lung Dis. 2010 Dec;14(12):1538-47.

Tags: Advocacy, Editorials, Policy, Regimen Change, TB Market

Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection

11/2010 - Zumla A, Atun R, Maeurer M, et; al. Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection. Trop Med Int Health. 2010 Nov 2; doi: 10.1111/j.1365-3156.2010.02665.x

Tags: Advocacy, Editorials, TB Burden

Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)

11/2010 - Kmentova I, Sutherland HS, Palmer BD, et. al. Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)

Tags: Drug Discovery, Pharmacokinetics, Preclinical Data

Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis

11/2010 - Ekins S, Kaneko T, Lipinski CA, et. al. Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis. Mol Biosyst. 2010 Nov;6(11):2316-24. doi: 10.1039/c0mb00104j.

Tags: Drug Discovery, Preclinical Data

PA-824 exhibits time-dependent activity in a murine model of tuberculosis

10/2010 - Ahmad Z, Peloquin CA, Singh RP, et. al. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother. 2011 Jan;55(1):239-45. doi: 10.1128/AAC.00849-10.

Tags: Drug Discovery, Pharmacokinetics, Preclinical Data, Pretomanid/PA-824

Current development and future prospects in chemotherapy of tuberculosis

7/2010 - Nuermberger EL, Spigelman MK, Yew WW. Current development and future prospects in chemotherapy of tuberculosis. Respirology. 2010 Jul;15(5):764-78. doi: 10.1111/j.1440-1843.2010.01775.x.

Tags: Bedaquiline (TMC-207), Clinical Development, Drug Discovery, Editorials, Global Pipeline, Moxifloxacin, Pretomanid/PA-824, TB Market

Pages